Actym Therapeutics, Inc.

We are solving a critical challenge in immuno-oncology: the need to switch “cold” tumors to “hot” in order to optimally engage anti-tumor immunity, all while avoiding systemic exposure to key cytokines which mediate the switch. Most IO drugs only work in a minority of patients. Actym’s lead product candidate, ACTM-838, utilizes our STACT™ biological platform to solve this challenge. Actym’s STACT™ (S. Typhimurium-Attenuated Cancer Therapy) platform harnesses the power of a systemically administered genetically modified bacterial vehicle to deliver multiplexed plasmid-encoded payloads directly to the site of disease, which are then locally amplified to produce a therapeutic effect. For ACTM-838, we utilize STACT™ to deliver and produce constitutively active STING within tumor-resident myeloid cells and IL-15plex in the tumor microenvironment, resulting in local engagement of both the innate and adaptive immune systems. We’re turning cold tumors hot while minimizing systemic immune activation. Why investors are paying attention: Key clinical updates from our Phase 1a/b trial are coming in 3Q 2025. Our STACT™ platform is highly modular, multi-faceted, and expandable beyond oncology. ACTM-838 is complementary to immunotherapies that are hindered by the immune-suppressive tumor microenvironment. It’s a fundamentally new approach to a long-standing problem. We’ve seen breakthroughs in drug delivery, what happens when delivery breakthroughs reshape medicine. It's happening again. Stay tuned.